| Literature DB >> 28134772 |
Aikaterina Siopi1, Olga Deda2, Vasiliki Manou3, Spyros Kellis4, Ioannis Kosmidis5, Despina Komninou6, Nikolaos Raikos7, Kosmas Christoulas8, Georgios A Theodoridis9, Vassilis Mougios10.
Abstract
Exercise is important in the prevention and treatment of the metabolic syndrome (MetS), a cluster of risk factors that raises morbidity. Metabolomics can facilitate the optimization of exercise prescription. This study aimed to investigate whether the response of the human urinary metabolic fingerprint to exercise depends on the presence of MetS or exercise mode. Twenty-three sedentary men (MetS, n = 9, and Healthy, n = 14) completed four trials: resting, high-intensity interval exercise (HIIE), continuous moderate-intensity exercise (CME), and resistance exercise (RE). Urine samples were collected pre-exercise and at 2, 4, and 24 h for targeted analysis by liquid chromatography-mass spectrometry. Time exerted the strongest differentiating effect, followed by exercise mode and health status. The greatest changes were observed in the first post-exercise samples, with a gradual return to baseline at 24 h. RE caused the greatest responses overall, followed by HIIE, while CME had minimal effect. The metabolic fingerprints of the two groups were separated at 2 h, after HIIE and RE; and at 4 h, after HIIE, with evidence of blunted response to exercise in MetS. Our findings show diverse responses of the urinary metabolic fingerprint to different exercise modes in men with and without metabolic syndrome.Entities:
Keywords: exercise mode; metabolic syndrome; metabolomics; urinary metabolites
Year: 2017 PMID: 28134772 PMCID: PMC5372208 DOI: 10.3390/metabo7010005
Source DB: PubMed Journal: Metabolites ISSN: 2218-1989
Characteristics of the participants at baseline.
| MetS ( | Healthy ( | |
|---|---|---|
| Age (years) | 46 ± 8 | 41 ± 7 |
| Weight (kg) | 100 ± 10 | 91 ± 15 |
| Height (m) | 1.80 ± 0.07 | 1.80 ± 0.07 |
| BMI (kg·m−2) | 31.0 ± 3.7 | 28.1 ± 4.2 |
| Waist circumference (cm) | 110 (103–117) | 99 (94–108) * |
| Body fat (% body weight) | 26.9 ± 5.5 | 22.7 ± 5.0 |
| Trunk fat (% area) | 37.7 ± 4.9 | 33.1 ± 7.3 |
| Visceral fat rating | 21 (15–24) | 15 (12–19) * |
| Serum glucose (mmol·L−1) | 5.9 (5.6–6.6) | 5.2 (5.0–5.4) *** |
| Serum triacylglycerols (mmol·L−1) | 1.9 (1.3–2.9) | 1.1 (0.9–1.5) ** |
| Serum total cholesterol (mmol·L−1) | 6.4 ± 1.3 | 5.2 ± 0.8 ** |
| HDL cholesterol (mmol·L−1) | 1.2 ± 0.3 | 1.4 ± 0.3 |
| LDL cholesterol (mmol·L−1) | 4.2 ± 1.2 | 3.1 ± 0.8 * |
| Systolic pressure (mm·Hg) | 140 ± 15 | 120 ± 9 *** |
| Diastolic pressure (mm·Hg) | 87 (84–98) | 76 (72–80) *** |
| 31.1 ± 4.2 | 37.0 ± 4.1 ** | |
| Resting heart rate (bpm) | 67 ± 10 | 64 ± 9 |
| HRmax (bpm) | 176 ± 11 | 179 ± 13 |
| HOMA2-IR | 3.06 ± 1.04 | 2.22 ± 0.82 * |
Data are mean ± SD or median (interquartile range). * p < 0.05, ** p < 0.01, *** p < 0.001: significantly different from MetS based on Student’s t test or Mann–Whitney U test, as appropriate.
Figure 1Overview of the experimental design. RE: resistance exercise, HIIE: high-intensity interval exercise, CME: continuous moderate-intensity exercise, REST: resting. Arrows indicate urine sampling.
Figure 2Heat map showing percent change from baseline in all measured metabolites at 2, 4 and 24 h for the three exercise modes in each group. Significant interactions (p < 0.05) from the three-way repeated-measure ANOVA are noted as follows: 1 exercise mode × group; 2 time × group; and 3 exercise mode × time. Significant main effects are noted as follows: 4 group; 5 exercise mode; and 6 time.
Figure 3Venn diagram of the results of the three-way ANOVA. The numbers show the sums of significant main effects and interactions referring to all 64 metabolites determined by UPLC-MS/MS (p < 0.05).
Figure 4Score plots for the PLS-DA models of pair wise comparisons for RE: (A) 0 h (blue circles) vs. 2 h (red squares); (B) 0 h (blue circles) vs. 4 h (green triangles); (C) 2 h (red squares) vs. 4 h (green triangles); (D) 2 h (red squares) vs. 24 h (yellow diamonds); and (E) 4 h (green triangles) vs. 24 h (yellow diamonds). Inserts are permutation plots. The MetS group is represented as 1 and the Healthy group as 2. R2X (cum), R2Y (cum), Q2Y (cum), and CV-ANOVA p value: (A) 0.513, 0.724, 0.603, and 5.93 × 10−7; (B) 0.383, 0.778, 0.619, and 3.36 × 10−6; (C) 0.491, 0.720, 0.604, and 5.18 × 10−7; (D) 0.437, 0.819, 0.660, and 6.04 × 10−7; and (E) 0.376, 0.793, 0.617, and 2.76 × 10−6, respectively.
Important metabolites in explaining the valid PLS-DA models.
| Group | Exercise Mode | Time | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIIE, 2 h | HIIE, 4 h | RE, 2 h | 2 h | 4 h | HIIE | RE | ||||||||||
| MetS vs. Healthy | MetS vs. Healthy | MetS vs. Healthy | HIIE vs. CME | CME vs. RE | HIIE vs. RE | CME vs. RE | 0 vs. 2 h | 0 vs. 4 h | 2 vs. 4 h | 2 vs. 24 h | 0 vs. 2 h | 0 vs. 4 h | 2 vs. 4 h | 2 vs. 24 h | 4 vs. 24 h | |
| 3-Methylhistidine | 1.69 ** | 1.03 ** | 1.63 | |||||||||||||
| 4-Hydroxyphenyllactate | −0.49 * | |||||||||||||||
| Acetylcarnitine | 1.07 * | |||||||||||||||
| Alanine | 1.84 ** | −0.58 *** | −0.61 *** | 3.16 *** | −0.65 *** | −0.73 *** | ||||||||||
| Arginine | −0.64 * | −0.35 * | −0.43 *** | 0.32 * | ||||||||||||
| Citrate | 0.26 ** | −0.35 *** | 0.48 *** | |||||||||||||
| Creatine | −0.45 *** | |||||||||||||||
| Creatinine | −0.53 *** | |||||||||||||||
| Cystine | −0.25 * | |||||||||||||||
| Cytosine | −0.29 | |||||||||||||||
| Dimethylamine | 0.51 *** | −0.22 *** | ||||||||||||||
| Glucose | 0.57 *** | −0.40 *** | ||||||||||||||
| Glutamate | −0.30 | |||||||||||||||
| Glutamine | 1.79 ** | 1.43 *** | −0.46 *** | |||||||||||||
| Guanine | 1.31 *** | 1.97 *** | 0.91 * | −0.74 *** | 2.69 *** | −0.77 *** | −0.76 * | |||||||||
| Histamine | −0.26 ** | |||||||||||||||
| Histidine | −0.29 * | |||||||||||||||
| Hypotaurine | 2.14 *** | |||||||||||||||
| Hypoxanthine | −0.39 | −0.77 *** | 10.21 *** | 1.57 | 6.38 *** | 7.01 *** | 1.85 *** | −0.55 *** | −0.89 *** | 16.78 *** | 7.45 *** | −0.94 *** | −0.90 *** | |||
| Inosine | −0.71 *** | 37.43 ** | 4.73 ** | 2.40 *** | 7.28 *** | −0.91 *** | ||||||||||
| Kynurenate | 0.81 | −0.55 *** | −0.51 *** | |||||||||||||
| Lactate | −0.93 ** | 60.84 *** | 21.59 *** | −0.92 ** | −0.96 *** | 58.70 *** | 5.83 | −0.87 *** | −0.98 *** | |||||||
| Lysine | 1.51 ** | 0.69 * | ||||||||||||||
| Methylamine | 0.65 ** | |||||||||||||||
| Monoisoamylamine | 0.68 * | −0.40 * | −0.36 *** | 1.41 *** | −0.50 *** | |||||||||||
| Proline | 0.81 * | |||||||||||||||
| Pyroglutamate | 1.47 *** | −0.50 *** | 1.85 *** | |||||||||||||
| Pyruvate | −0.75 *** | 16.54 *** | 18.25 *** | −0.90 *** | −0.94 *** | |||||||||||
| Riboflavin | −0.81 * | −0.76 | −0.69 * | |||||||||||||
| Serine | 1.13 *** | |||||||||||||||
| Sucrose | −0.72 * | |||||||||||||||
| Thiamine | −0.58 | −0.51 * | 0.42 | |||||||||||||
| Threonine | 1.70 ** | |||||||||||||||
| Thymine | 1.88 ** | |||||||||||||||
| Trimethylamine | −0.44 *** | 0.19 | ||||||||||||||
| Uracil | −0.27 * | |||||||||||||||
| Uridine | 0.53 | −0.41 * | −0.44 * | −0.43 ** | −0.13 | −0.39 * | ||||||||||
| Xanthine | 0.94 *** | −0.55 *** | −0.51 *** | −0.51 *** | ||||||||||||
Numbers indicate fold change and appear wherever a metabolite contributed to the discrimination. For example, the first number, 1.69, means that the value in Healthy was 1.69 fold higher than the value in MetS. * p < 0.05, ** p < 0.01, *** p < 0.001, significant difference following Student’s t test.